A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including ...
MedPage Today on MSN
FDA halts two gene therapy trials after child develops brain tumor
Studies of Hunter and Hurler syndromes on hold ...
Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...
The Food and Drug Administration paused trials for two experimental gene therapies from Regenxbio after one child developed a ...
The disease leads to the progressive growth of fluid-filled cysts in the kidneys, often resulting in kidney failure and other ...
The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing ...
GlobalData on MSN
FDA puts REGENXBIO gene therapy trials on hold after brain tumour
A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.
GlobalData on MSN
Genespire to take rare disease gene therapy to clinic in 2026
GENE202 is a single dose gene therapy for patients with rare metabolic disease, methylmalonic acidaemia.
Jan 27 (Reuters) - Intellia Therapeutics said on Tuesday that the U.S. drug regulator has lifted a clinical hold on one of ...
Under the agreement, participating states will receive “discounts and rebates” from the drugmakers if the treatments don’t ...
(Yicai) Jan. 28 -- Chinese medical researchers have made a breakthrough in gene therapy that overcomes the limitations of ...
University of California San Diego-led team has discovered that restoring a key cardiac protein called connexin‑43 in a mouse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results